HUP0000576A2 - A zöld porfirinek alkalmazása szekunder szürkehályogok kezelésére alkalmas gyógyszerek készítésében - Google Patents

A zöld porfirinek alkalmazása szekunder szürkehályogok kezelésére alkalmas gyógyszerek készítésében

Info

Publication number
HUP0000576A2
HUP0000576A2 HU0000576A HUP0000576A HUP0000576A2 HU P0000576 A2 HUP0000576 A2 HU P0000576A2 HU 0000576 A HU0000576 A HU 0000576A HU P0000576 A HUP0000576 A HU P0000576A HU P0000576 A2 HUP0000576 A2 HU P0000576A2
Authority
HU
Hungary
Prior art keywords
treatment
medicament
manufacture
green porphyrins
secondary cataracts
Prior art date
Application number
HU0000576A
Other languages
English (en)
Inventor
Nick Bussanich
Claude A. A. Hariton
Gustav Huber
Julia G. Levy
David R. Mallek
Howard E. Meadows
Anna M. Richter
Jack Rootman
Danielle Wenkstern
Original Assignee
Ciba Vision Ag, Hettlingen
Qlt Photo Therapeutics, Inc.
The University Of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Vision Ag, Hettlingen, Qlt Photo Therapeutics, Inc., The University Of British Columbia filed Critical Ciba Vision Ag, Hettlingen
Publication of HUP0000576A2 publication Critical patent/HUP0000576A2/hu
Publication of HUP0000576A3 publication Critical patent/HUP0000576A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány tárgyát a fotodinámiás kezelés (PDT) alkalmazása képeziszekunder szürkehályogok megelőzésére, a visszamaradt, epiteliálissejtek elpusztítása révén, pontosabban a zöld porfirinek mintfényérzékenyítő anyagok alkalmazása az ilyen PDT-kezelés céljára. Ó
HU0000576A 1996-12-10 1997-12-08 Use of green porphyrins for the manufacture of a medicament for the treatment of secondary cataracts HUP0000576A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/762,854 US6043237A (en) 1996-12-10 1996-12-10 Use of photodynamic therapy for prevention of secondary cataracts
PCT/CA1997/000949 WO1998025610A1 (en) 1996-12-10 1997-12-08 Use of green porphyrins for the manufacture of a medicament for the treatment of secondary cataracts

Publications (2)

Publication Number Publication Date
HUP0000576A2 true HUP0000576A2 (hu) 2000-11-28
HUP0000576A3 HUP0000576A3 (en) 2002-09-30

Family

ID=25066203

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000576A HUP0000576A3 (en) 1996-12-10 1997-12-08 Use of green porphyrins for the manufacture of a medicament for the treatment of secondary cataracts

Country Status (15)

Country Link
US (2) US6043237A (hu)
EP (1) EP0948329A1 (hu)
JP (1) JP2001505885A (hu)
KR (1) KR20000057510A (hu)
CN (1) CN1246054A (hu)
AR (1) AR010754A1 (hu)
AU (1) AU737204B2 (hu)
CA (1) CA2273010C (hu)
HU (1) HUP0000576A3 (hu)
IL (1) IL130404A0 (hu)
NO (1) NO992808L (hu)
NZ (1) NZ336196A (hu)
PL (1) PL333951A1 (hu)
WO (1) WO1998025610A1 (hu)
ZA (1) ZA9711104B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2266622C (en) * 1996-09-27 2006-08-15 Hyal Pharmaceutical Corporation Hyaluronic drug delivery system
ES2237146T3 (es) 1998-08-28 2005-07-16 Destiny Pharma Limited Derivados de porfirina, su uso en terapia fotodinamica y dispositivos medicos que los contienen.
US6828439B1 (en) 1999-02-26 2004-12-07 Advanced Research And Technology Institute, Inc. Compounds, composition, and methods for photodynamic therapy
US7022843B1 (en) 1999-04-14 2006-04-04 The University Of British Columbia β,β′-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US6319273B1 (en) * 1999-12-16 2001-11-20 Light Sciences Corporation Illuminating device for treating eye disease
US6673067B1 (en) * 2000-01-31 2004-01-06 Gholam A. Peyman System and method for thermally and chemically treating cells at sites of interest in the body to impede cell proliferation
WO2002019594A2 (en) * 2000-08-02 2002-03-07 Arizona Board Of Regents, Acting On Behalf Of Arizona State University Scanning fluorescence lifetime microscope: directed evolution
US7211603B1 (en) 2000-09-25 2007-05-01 Indiana University Research And Technology Corporation Enediyne compounds and methods related thereto
US6514995B1 (en) 2000-09-25 2003-02-04 Advanced Research And Technology Institute, Inc. Enediyne compounds and methods related thereto
AU2895502A (en) * 2000-12-20 2002-07-01 Alcon Universal Ltd Solution for removing cataracts via liquefracture
US7753943B2 (en) * 2001-02-06 2010-07-13 Qlt Inc. Reduced fluence rate PDT
AU2002233092A1 (en) 2001-02-15 2002-08-28 Qlt Inc. Reduction or prevention of pdt related inflammation
US6838074B2 (en) 2001-08-08 2005-01-04 Bristol-Myers Squibb Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
ATE390121T1 (de) * 2001-11-02 2008-04-15 Univ Alberta Micelle-zusammensetzungen enthaltend pegylierten phospholipide und einen photosensibilisator
US6723750B2 (en) 2002-03-15 2004-04-20 Allergan, Inc. Photodynamic therapy for pre-melanomas
ATE547416T1 (de) 2002-07-24 2012-03-15 Dermira Canada Inc Pyrazolylbenzothiazolderivate und deren verwendung als therapeutische mittel
CA2500877A1 (en) * 2002-10-03 2004-04-15 Light Sciences Corporation Excitation of photoreactive compounds in eye tissue
EP1605847B1 (en) * 2003-03-07 2009-09-16 Board Of Regents, The University Of Texas System Antibody-targeted photodynamic therapy
US20050048109A1 (en) * 2003-08-26 2005-03-03 Ceramoptec Industries, Inc. Non-polar photosensitizer formulations for photodynamic therapy
US7252662B2 (en) * 2004-11-02 2007-08-07 Lenticular Research Group Llc Apparatus and processes for preventing or delaying one or more symptoms of presbyopia
US7468434B2 (en) * 2004-12-22 2008-12-23 The University Of Hong Kong Diazene-bridge crown ether lithium compounds and methods for their use
AU2006213997A1 (en) 2005-02-19 2006-08-24 Lenticular Research Group Llc Apparatus and processes for preventing or delaying onset or progression of age-related cataract
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
EP2802302A4 (en) * 2012-01-10 2015-09-23 Avedro Inc APPLYING ENERGY FOR MEDICAL TREATMENTS
WO2013148896A1 (en) 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Ocular treatment solutions, delivery devices and delivery augmentation methods
WO2013148895A1 (en) * 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Ocular cross-linking system and method for sealing corneal wounds
EP2830637A4 (en) 2012-03-29 2016-03-16 Cxl Ophthalmics Llc COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES RELATED TO OXIDATIVE STRESS
CN106620893B (zh) 2015-07-23 2021-07-30 爱博诺德(北京)医疗科技股份有限公司 用于眼部疾病光治疗的材料
US20230165718A1 (en) * 2021-11-29 2023-06-01 Alan Neil Glazier Methods, devices, and systems for treating lens protein aggregation diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202252A (en) * 1982-03-05 1993-04-13 Houston Biotechnology Inc. Monoclonal antibodies against lens epithelial cells and methods for preventing proliferation of remnant lens epithelial cells after extracapsular extraction
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US5171749A (en) * 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US4920143A (en) * 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US5401880A (en) * 1987-06-04 1995-03-28 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
US4966577A (en) * 1988-03-16 1990-10-30 Allergan, Inc. Prevention of lens-related tissue growth in the eye
US5273751A (en) * 1988-03-25 1993-12-28 Seymour Dubroff Composition for preventing clouding of paosterior capsule after extracapsular cataract eye surgery and method of performing cataract surgery
US5375611A (en) * 1993-01-26 1994-12-27 Pharmacia Ab Method for preventing secondary cataract
US5422362A (en) * 1993-07-29 1995-06-06 Quadra Logic Technologies, Inc. Method to inhibit restenosis
US5445637A (en) * 1993-12-06 1995-08-29 American Cyanamid Company Method and apparatus for preventing posterior capsular opacification
US5798349A (en) * 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
CA2185644C (en) * 1994-03-14 2011-04-12 Joan W. Miller Use of green porphyrins in ocular diagnosis and therapy

Also Published As

Publication number Publication date
CA2273010A1 (en) 1998-06-18
ZA9711104B (en) 1998-07-10
WO1998025610A1 (en) 1998-06-18
NO992808D0 (no) 1999-06-09
NZ336196A (en) 2000-10-27
EP0948329A1 (en) 1999-10-13
HUP0000576A3 (en) 2002-09-30
AU737204B2 (en) 2001-08-09
JP2001505885A (ja) 2001-05-08
AU5220298A (en) 1998-07-03
AR010754A1 (es) 2000-07-12
IL130404A0 (en) 2000-06-01
PL333951A1 (en) 2000-01-31
US6043237A (en) 2000-03-28
CN1246054A (zh) 2000-03-01
KR20000057510A (ko) 2000-09-15
CA2273010C (en) 2007-03-13
NO992808L (no) 1999-08-09
US6248734B1 (en) 2001-06-19

Similar Documents

Publication Publication Date Title
HUP0000576A2 (hu) A zöld porfirinek alkalmazása szekunder szürkehályogok kezelésére alkalmas gyógyszerek készítésében
IT1333697B (hu)
HK1026691A1 (en) Substituted benzimidazoles and their use for treating retroviral infection
CR7330A (es) Procedimiento para tratar enfermedades neovasculares oculares
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
EA200501251A1 (ru) Антинеопластические комбинации
WO2002096366A3 (en) Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
AR032293A1 (es) Estuche farmaceutico
PT912184E (pt) Utilizacao de um derivado de k-252a para o tratamento de doencas do sietma nervoso central ou periferico e sobre-producao de citoquina
EA200300544A1 (ru) Эффективные противоопухолевые лекарственные средства
TR199901104T2 (xx) Farmas�tik bile�ikler.
NO20024486D0 (no) Forbedret behandling av neovaskularisering
WO2001024825A3 (en) Significance of dosimetry in photodynamic therapy of injured arteries
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
PT1267931E (pt) Derivados de rodamina para o diagnostico e tratamento fotodinamicos
BR0015938A (pt) Uso de antagonistas beta-adrenoceptores para a fabricação de um medicamento para o tratamento de desordens da retina externa
GB2360785B (en) Porphyrins and related compounds
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
EP1570859A3 (en) Improved treatment of neovascularization
UY24769A1 (es) Derivados de vinilpirrolidinon-cefalosporina
AU2002322213A1 (en) Treatment of macular edema with photodynamic therapy